nach oben

Erschienen in:

02.05.2018 | Review

Microbiota and metabolic diseases

verfasst von: Alessia Pascale, Nicoletta Marchesi, Cristina Marelli, Adriana Coppola, Livio Luzi, Stefano Govoni, Andrea Giustina, Carmine Gazzaruso

Erschienen in: Endocrine | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

The microbiota is a complex ecosystem of microorganisms consisting of bacteria, viruses, protozoa, and fungi, living in different districts of the human body, such as the gastro-enteric tube, skin, mouth, respiratory system, and the vagina. Over 70% of the microbiota lives in the gastrointestinal tract in a mutually beneficial relationship with its host. The microbiota plays a major role in many metabolic functions, including modulation of glucose and lipid homeostasis, regulation of satiety, production of energy and vitamins. It exerts a role in the regulation of several biochemical and physiological mechanisms through the production of metabolites and substances. In addition, the microbiota has important anti-carcinogenetic and anti-inflammatory actions. There is growing evidence that any modification in the microbiota composition can lead to several diseases, including metabolic diseases, such as obesity and diabetes, and cardiovascular diseases. This is because alterations in the microbiota composition can cause insulin resistance, inflammation, vascular, and metabolic disorders. The causes of the microbiota alterations and the mechanisms by which microbiota modifications can act on the development of metabolic and cardiovascular diseases have been reported. Current and future preventive and therapeutic strategies to prevent these diseases by an adequate modulation of the microbiota have been also discussed.

R. Sender, S. Fuchs, R. Milo, Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016). https://doi.org/10.1371/journal.pbio.1002533 PubMedPubMedCentralCrossRef

C. Palmer, E.M. Bik, D.B. DiGiulio, D.A. Relman, P.O. Brown, Development of the human infant intestinal microbiota. PLoS Biol. 5, 1556–1573 (2007). https://doi.org/10.1371/journal.pbio.0050177 CrossRef

A. Pingitore, E.S. Chambers, T. Hill, I.R. Maldonado, B. Liu, G. Bewick, D.J. Morrison, T. Preston, G.A. Wallis, C. Tedford, R. Castañera González, G.C. Huang, P. Choudhary, G. Frost, S.J. Persaud, The diet-derived short chain fatty acid propionate improves beta-cell function in humans and stimulates insulin secretion from human islets in vitro. Diabetes Obes. Metab. 19, 257–265 (2017). https://doi.org/10.1111/dom.12811 PubMedCrossRef

F. Bäckhed, J. Roswall, Y. Peng, Q. Feng, H. Jia, P. Kovatcheva-Datchary, Y. Li, Y. Xia, H. Xie, H. Zhong, M.T. Khan, J. Zhang, J. Li, L. Xiao, J. Al-Aama, D. Zhang, Y.S. Lee, D. Kotowska, C. Colding, V. Tremaroli, Y. Yin, S. Bergman, X. Xu, L. Madsen, K. Kristiansen, J. Dahlgren, J. Wang, W. Jun, Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690–703 (2015). https://doi.org/10.1016/j.chom.2015.04.004 PubMedCrossRef

B.S. Ramakrishna, The normal bacterial flora of the human intestine and its regulation. J. Clin. Gastroenterol. 41, S2–S6 (2007)CrossRef

F. Bäckhed, C.M. Fraser, Y. Ringel, M.E. Sanders, R.B. Sartor, P.M. Sherman, J. Versalovic, V. Young, B.B. Finlay, Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 12, 611–622 (2012). https://doi.org/10.1016/j.chom.2012.10.012 PubMedCrossRef

Human Microbiome Project C., A framework for human microbiome research. Nature 486, 215–221 (2012). https://doi.org/10.1038/nature11209 CrossRef

E.A. Grice, J.A. Segre, The human microbiome: our second genome. Annu. Rev. Genom. Hum. Genet. 13, 151–170 (2012). https://doi.org/10.1146/annurev-genom-090711-163814 CrossRef

D.A. Hill, D. Artis, Intestinal bacteria and the regulation of immune cell homeostasis. Annu. Rev. Immunol. 28, 623–667 (2010). https://doi.org/10.1146/annurev-immunol-030409-101330 PubMedPubMedCentralCrossRef

10.

C. Mueller, A.J. Macpherson, Layers of mutualism with commensal bacteria protect us from intestinal inflammation. Gut 55, 276–284 (2006)PubMedPubMedCentralCrossRef

11.

F. Guarner, J.-R. Malagelada, Gut flora in health and disease. Lancet 361, 512–519 (2003). https://doi.org/10.1016/S0140-6736(03)12489-0 PubMedCrossRef

12.

I. Rowland, G. Gibson, A. Heinken, K. Scott, J. Swann, I. Thiele, K. Tuohy, Gut microbiota functions: metabolism of nutrients and other food components. Eur. J. Nutr. 57(1), 1–24 (2017). https://doi.org/10.1007/s00394-017-1445-8 PubMedPubMedCentralCrossRef

13.

L. Capurso, Il Microbiota intestinale. Recent. Prog. Med. 107, 257–266 (2016)

14.

E.F. Enright, C.G.M. Gahan, S.A. Joyce, B.T. Griffin, The impact of the gut microbiota on drug metabolism and clinical outcome. Yale J. Biol. Med. 89, 375–382 (2016)PubMedPubMedCentral

15.

D.R. Donohoe, N. Garge, X. Zhang, W. Sun, T.M. O’Connell, M.K. Bunger, S.J. Bultman, The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 13, 517–526 (2011). https://doi.org/10.1016/j.cmet.2011.02.018 PubMedPubMedCentralCrossRef

16.

N. Kobyliak, O. Virchenko, T. Falalyeyeva, Pathophysiological role of host microbiota in the development of obesity. Nutr. J. 15, 1–12 (2016). https://doi.org/10.1186/s12937-016-0166-9 CrossRef

17.

Y.E. Borre, G.W. O’Keeffe, G. Clarke, C. Stanton, T.G. Dinan, J.F. Cryan, Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol. Med. 20, 509–518 (2014). https://doi.org/10.1016/j.molmed.2014.05.002 PubMedCrossRef

18.

D.J. Morrison, T. Preston, Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7, 189–200 (2016). https://doi.org/10.1080/19490976.2015.1134082 PubMedPubMedCentralCrossRef

19.

G. den Besten, K. van Eunen, A.K. Groen, K. Venema, D.-J. Reijngoud, B.M. Bakker, The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325–2340 (2013). https://doi.org/10.1194/jlr.R036012 CrossRef

20.

G.T. Macfarlane, G.R. Gibson, J.H. Cummings, Comparison of fermentation reactions in different regions of the human colon. J. Appl. Bacteriol. 72, 57–64 (1992). https://doi.org/10.1111/j.1365-2672.1992.tb04882.x PubMedCrossRef

21.

J.G. LeBlanc, F. Chain, R. Martín, L.G. Bermúdez-Humarán, S. Courau, P. Langella, Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb. Cell Fact. 16, 1–10 (2017). https://doi.org/10.1186/s12934-017-0691-z CrossRef

22.

C.K. Chakraborti, New-found link between microbiota and obesity. World J. Gastrointest. Pathophysiol. 6, 110–119 (2015). https://doi.org/10.4291/wjgp.v6.i4.110 PubMedPubMedCentralCrossRef

23.

X. Li, Y. Shimizu, I. Kimura, Gut microbial metabolite short-chain fatty acids and obesity. Biosci. Micro., Food Heal. 36, 135–140 (2017). https://doi.org/10.12938/bmfh.17-010 CrossRef

24.

P. Schönfeld, L. Wojtczak, Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J. Lipid Res. 57, 943–954 (2016). https://doi.org/10.1194/jlr.R067629 PubMedPubMedCentralCrossRef

25.

D.N. Cooper, R.J. Martin, N.L. Keim, Does whole grain consumption alter gut microbiota and satiety? Healthc. (Basel, Switz.) 3, 364–392 (2015). https://doi.org/10.3390/healthcare3020364 CrossRef

26.

A. Everard, P.D. Cani, Gut microbiota and GLP-1. Rev. Endocr. Metab. Disord. 15, 189–196 (2014)PubMedCrossRef

27.

G. Frost, M.L. Sleeth, M. Sahuri-Arisoylu, B. Lizarbe, S. Cerdan, L. Brody, J. Anastasovska, S. Ghourab, M. Hankir, S. Zhang, D. Carling, J.R. Swann, G. Gibson, A. Viardot, D. Morrison, E.L. Thomas, J.D. Bell, The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014). https://doi.org/10.1038/ncomms4611 PubMedPubMedCentralCrossRef

28.

L.E.M. Willemsen, M.A. Koetsier, S.J.H. van Deventer, E.A.F. van Tol, Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. Gut 52, 1442–1447 (2003)PubMedPubMedCentralCrossRef

29.

F.J. Cousin, S. Jouan-Lanhouet, N. Theret, C. Brenner, E. Jouan, G. Le Moigne-Muller, M.-T. Dimanche-Boitrel, G. Jan, The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer. Oncotarget 7, 7161–7178 (2016). https://doi.org/10.18632/oncotarget.6881 PubMedPubMedCentralCrossRef

30.

J. Ni, G.D. Wu, L. Albenberg, V.T. Tomov, Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 14, 573–584 (2017)PubMedPubMedCentral

31.

H.J. Flint, E.A. Bayer, Plant cell wall breakdown by anaerobic microorganisms from the mammalian digestive tract. Ann. New Y. Acad. Sci. 1125, 280–288 (2008)CrossRef

32.

P. van den Abbeele, P. Gérard, S. Rabot, A. Bruneau, S. El Aidy, M. Derrien, M. Kleerebezem, E.G. Zoetendal, H. Smidt, W. Verstraete, T. van de Wiele, S. Possemiers, Arabinoxylans and inulin differentially modulate the mucosal and luminal gut microbiota and mucin-degradation in humanized rats. Environ. Microbiol. 13, 2667–2680 (2011). https://doi.org/10.1111/j.1462-2920.2011.02533.x PubMedCrossRef

33.

A.L. McOrist, R.B. Miller, A.R. Bird, J.B. Keogh, M. Noakes, D.L. Topping, M.A. Conlon, Fecal butyrate levels vary widely among individuals but are usually increased by a diet high in resistant starch. J. Nutr. 141, 883–889 (2011). https://doi.org/10.3945/jn.110.128504 PubMedCrossRef

34.

C. Grootaert, P. Van Den Abbeele, M. Marzorati, W.F. Broekaert, C.M. Courtin, J.A. Delcour, W. Verstraete, T. Van De Wiele, Comparison of prebiotic effects of arabinoxylan oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol. Ecol. 69, 231–242 (2009). https://doi.org/10.1111/j.1574-6941.2009.00712.x PubMedCrossRef

35.

M. Begley, C. Hill, C.G.M. Gahan, Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 72, 1729–1738 (2006). https://doi.org/10.1128/AEM.72.3.1729-1738.2006 PubMedPubMedCentralCrossRef

36.

WHO | Obesity and overweight. (WHO, Geneva, Switzerland, 2018)

37.

K. Ball, G. Mishra, D. Crawford, Which aspects of socioeconomic status are related to obesity among men and women? Int. J. Obes. Relat. Metab. Disord. 26, 559–565 (2002). https://doi.org/10.1038/sj.ijo.0801960 PubMedCrossRef

38.

J.F. Rawls, M.A. Mahowald, R.E. Ley, J.I. Gordon, Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell 127, 423–433 (2018). https://doi.org/10.1016/j.cell.2006.08.043 CrossRef

39.

R. Ley, P. Turnbaugh, S. Klein, J. Gordon, Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006). https://doi.org/10.1038/nature4441021a PubMedCrossRef

40.

M.A. Hildebrandt, C. Hoffman, S.A. Sherrill-Mix, S.A. Keilbaugh, M. Hamady, Y.-Y. Chen, R. Knight, R.S. Ahima, F. Bushman, G.D. Wu, High fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 137, 1712–1716 (2009). https://doi.org/10.1053/j.gastro.2009.08.042 CrossRef

41.

P.J. Turnbaugh, F. Bäckhed, L. Fulton, J.I. Gordon, Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213–223 (2008). https://doi.org/10.1016/j.chom.2008.02.015 PubMedPubMedCentralCrossRef

42.

M.A. Conlon, A.R. Bird, The impact of diet and lifestyle on gut microbiota and human health. Nutrients 7, 17–44 (2015). https://doi.org/10.3390/nu7010017 CrossRef

43.

J. Hamzelou, Antibiotic overuse may promote obesity. New Sci. 213, 8–9 (2012). https://doi.org/10.1016/S0262-4079(12)60797-0 CrossRef

44.

L. Trasande, J. Blustein, M. Liu, E. Corwin, L.M. Cox, M.J. Blaser, Infant antibiotic exposures and early-life body mass. Int. J. Obes. (Lond.). 37, 16–23 (2013). https://doi.org/10.1038/ijo.2012.132 CrossRef

45.

L. Dethlefsen, D.A. Relman, Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. U.S.A. 108, Suppl, 4554–4561 (2011). https://doi.org/10.1073/pnas.1000087107 PubMedCrossRef

46.

P. Vangay, T. Ward, J.S. Gerber, D. Knights, Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe 17, 553–564 (2015). https://doi.org/10.1016/J.CHOM.2015.04.006 PubMedPubMedCentralCrossRef

47.

F. Bäckhed, H. Ding, T. Wang, L.V. Hooper, G.Y. Koh, A. Nagy, C.F. Semenkovich, J.I. Gordon, The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. U.S.A. 101, 15718–15723 (2004). https://doi.org/10.1073/pnas.0407076101 PubMedPubMedCentralCrossRef

48.

P.J. Turnbaugh, R.E. Ley, M.A. Mahowald, V. Magrini, E.R. Mardis, J.I. Gordon, An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006). https://doi.org/10.1038/nature05414 PubMedCrossRef

49.

A.P. Liou, M. Paziuk, J.M. Luevano, S. Machineni, P.J. Turnbaugh, L.M. Kaplan, Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 5, 178ra41 (2013). https://doi.org/10.1126/scitranslmed.3005687 PubMedPubMedCentralCrossRef

50.

S. Kersten, S. Mandard, N.S. Tan, P. Escher, D. Metzger, P. Chambon, F.J. Gonzalez, B. Desvergne, W. Wahli, Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275, 28488–28493 (2000). https://doi.org/10.1074/jbc.M004029200 PubMedCrossRef

51.

E.M. Cushing, X. Chi, K.L. Sylvers, S.K. Shetty, M.J. Potthoff, B.S.J. Davies, Angiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting. Mol. Metab. 6, 809–818 (2017). https://doi.org/10.1016/j.molmet.2017.06.007 PubMedPubMedCentralCrossRef

52.

F. Bäckhed, J.K. Manchester, C.F. Semenkovich, J.I. Gordon, Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. U.S.A. 104, 979–984 (2007). https://doi.org/10.1073/pnas.0605374104 PubMedPubMedCentralCrossRef

53.

N.E. Boutagy, R.P. McMillan, M.I. Frisard, M.W. Hulver, Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie 124, 11–20 (2016). https://doi.org/10.1016/j.biochi.2015.06.020 PubMedCrossRef

54.

H. Ghanim, S. Abuaysheh, C.L. Sia, K. Korzeniewski, A. Chaudhuri, J.M. Fernandez-Real, P. Dandona, Increase in plasma endotoxin concentrations and the expression of toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: Implications for insulin resistance. Diabetes Care 32, 2281–2287 (2009). https://doi.org/10.2337/dc09-0979 PubMedPubMedCentralCrossRef

55.

P.D. Cani, J. Amar, M.A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, A.M. Neyrinck, F. Fava, K.M. Tuohy, C. Chabo, A. Waget, E. Delmée, B. Cousin, T. Sulpice, B. Chamontin, J. Ferrières, J.F. Tanti, G.R. Gibson, L. Casteilla, N.M. Delzenne, M.C. Alessi, R. Burcelin, Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007). https://doi.org/10.2337/db06-1491 PubMedCrossRef

56.

M.M. Mihaylova, R.J. Shaw, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell. Biol. 13, 1016–1023 (2011). https://doi.org/10.1038/ncb2329 PubMedPubMedCentralCrossRef

57.

E. Le Poul, C. Loison, S. Struyf, J.-Y. Springael, V. Lannoy, M.-E. Decobecq, S. Brezillon, V. Dupriez, G. Vassart, J. Van Damme, M. Parmentier, M. Detheux, Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481–25489 (2003). https://doi.org/10.1074/jbc.M301403200 PubMedCrossRef

58.

A.J. Brown, S.M. Goldsworthy, A.A. Barnes, M.M. Eilert, L. Tcheang, D. Daniels, A.I. Muir, M.J. Wigglesworth, I. Kinghorn, N.J. Fraser, N.B. Pike, J.C. Strum, K.M. Steplewski, P.R. Murdock, J.C. Holder, F.H. Marshall, P.G. Szekeres, S. Wilson, D.M. Ignar, S.M. Foord, A. Wise, S.J. Dowell, The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312–11319 (2003). https://doi.org/10.1074/jbc.M211609200 PubMedCrossRef

59.

B.S. Samuel, A. Shaito, T. Motoike, F.E. Rey, F. Backhed, J.K. Manchester, R.E. Hammer, S.C. Williams, J. Crowley, M. Yanagisawa, J.I. Gordon, Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. 105, 16767–16772 (2008)PubMedCrossRef

60.

M. Bjursell, T. Admyre, M. Göransson, A.E. Marley, D.M. Smith, J. Oscarsson, M. Bohlooly-Y, Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am. J. Physiol. Metab. 300, E211–E220 (2010). https://doi.org/10.1152/ajpendo.00229.2010 CrossRef

61.

V.K. Ridaura, J.J. Faith, F.E. Rey, J. Cheng, A.E. Duncan, A.L. Kau, N.W. Griffin, V. Lombard, B. Henrissat, J.R. Bain, M.J. Muehlbauer, O. Ilkayeva, C.F. Semenkovich, K. Funai, D.K. Hayashi, B.J. Lyle, M.C. Martini, L.K. Ursell, J.C. Clemente, W. Van Treuren, W.A. Walters, R. Knight, C.B. Newgard, A.C. Heath, J.I. Gordon, Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013). https://doi.org/10.1126/science.1241214 PubMedCrossRef

62.

N.-R. Shin, J.-C. Lee, H.-Y. Lee, M.-S. Kim, T.W. Whon, M.-S. Lee, J.-W. Bae, An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014). https://doi.org/10.1136/gutjnl-2012-303839 PubMedCrossRef

63.

American Diabetes Association A.D., Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1), S62–S69 (2010). https://doi.org/10.2337/dc10-S062 CrossRef

64.

WHO Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. (WHO, Geneva, Switzerland, 2013)

65.

F. Navab-Moghadam, M. Sedighi, M.E. Khamseh, F. Alaei-Shahmiri, M. Talebi, S. Razavi, N. Amirmozafari, The association of type II diabetes with gut microbiota composition. Microb. Pathog. 110, 630–636 (2017). https://doi.org/10.1016/j.micpath.2017.07.034 PubMedCrossRef

66.

H. Wu, E. Esteve, V. Tremaroli, M.T. Khan, R. Caesar, L. Mannerås-Holm, M. Ståhlman, L.M. Olsson, M. Serino, M. Planas-Fèlix, G. Xifra, J.M. Mercader, D. Torrents, R. Burcelin, W. Ricart, R. Perkins, J.M. Fernàndez-Real, F. Bäckhed, Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017). https://doi.org/10.1038/nm.4345 PubMedCrossRef

67.

M.C. De Goffau, S. Fuentes, B. Van Den Bogert, H. Honkanen, W.M. De Vos, G.W. Welling, H. Hyöty, H.J.M. Harmsen, Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia 57, 1569–1577 (2014). https://doi.org/10.1007/s00125-014-3274-0 PubMedCrossRef

68.

S. Hasan, V. Aho, P. Pereira, L. Paulin, S.B. Koivusalo, P. Auvinen, J.G. Eriksson, Gut microbiome in gestational diabetes: a cross-sectional study of mothers and offspring 5 years postpartum. Acta Obstet. Gynecol. Scand. 97, 38–46 (2018). https://doi.org/10.1111/aogs.13252 PubMedCrossRef

69.

N. Larsen, F.K. Vogensen, F.W.J. Van Den Berg, D.S. Nielsen, A.S. Andreasen, B.K. Pedersen, W.A. Al-Soud, S.J. Sørensen, L.H. Hansen, M. Jakobsen, Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5, e9085 (2010). https://doi.org/10.1371/journal.pone.0009085 PubMedPubMedCentralCrossRef

70.

D. Ríos-Covián, P. Ruas-Madiedo, A. Margolles, M. Gueimonde, C.G. de Los Reyes-Gavilán, N. Salazar, Intestinal short chain fatty acids and their link with diet and human health. Front. Microbiol. 7, 185 (2016). https://doi.org/10.3389/fmicb.2016.00185 PubMedPubMedCentralCrossRef

71.

Z. Gao, J. Yin, J. Zhang, R.E. Ward, R.J. Martin, M. Lefevre, W.T. Cefalu, J. Ye, Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517 (2009). https://doi.org/10.2337/db08-1637 PubMedPubMedCentralCrossRef

72.

H.V. Lin, A. Frassetto, E.J. Kowalik, A.R. Nawrocki, M.M. Lu, J.R. Kosinski, J.A. Hubert, D. Szeto, X. Yao, G. Forrest, D.J. Marsh, Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE 7, e35240 (2012). https://doi.org/10.1371/journal.pone.0035240 PubMedPubMedCentralCrossRef

73.

R.J. Perry, L. Peng, N.A. Barry, G.W. Cline, D. Zhang, R.L. Cardone, K.F. Petersen, R.G. Kibbey, A.L. Goodman, G.I. Shulman, Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature 534, 213–217 (2016). https://doi.org/10.1038/nature18309 PubMedPubMedCentralCrossRef

74.

S. Devaraj, P. Hemarajata, J. Versalovic, The human gut microbiome and body metabolism: Implications for obesity and diabetes. Clin. Chem. 59, 617–628 (2013)PubMedPubMedCentralCrossRef

75.

M.A.R. Vinolo, H.G. Rodrigues, R.T. Nachbar, R. Curi, Regulation of inflammation by short chain fatty acids. Nutrients 3, 858–876 (2011)PubMedPubMedCentralCrossRef

76.

A. Vrieze, E. Van Nood, F. Holleman, J. Salojärvi, R.S. Kootte, J.F.W.M. Bartelsman, G.M. Dallinga-Thie, M.T. Ackermans, M.J. Serlie, R. Oozeer, M. Derrien, A. Druesne, J.E.T. Van Hylckama Vlieg, V.W. Bloks, A.K. Groen, H.G.H.J. Heilig, E.G. Zoetendal, E.S. Stroes, W.M. De Vos, J.B.L. Hoekstra, M. Nieuwdorp, Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–6.e7 (2012). https://doi.org/10.1053/j.gastro.2012.06.031 PubMedCrossRef

77.

P.D. Cani, N.M. Delzenne, The role of the gut microbiota in energy metabolism and metabolic disease. Curr. Pharm. Des. 15, 1546–1558 (2009). https://doi.org/10.2174/138161209788168164 PubMedCrossRef

78.

P.D. Cani, S. Possemiers, T. Van De Wiele, Y. Guiot, A. Everard, O. Rottier, L. Geurts, D. Naslain, A. Neyrinck, D.M. Lambert, G.G. Muccioli, N.M. Delzenne, Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58, 1091–1103 (2009). https://doi.org/10.1136/gut.2008.165886 PubMedPubMedCentralCrossRef

79.

S. Hædersdal, A. Lund, F.K. Knop, T. Vilsbøll, The role of glucagon in the pathophysiology and treatment of type 2 diabetes. Mayo Clin. Proc. 93, 217–239 (2018). https://doi.org/10.1016/j.mayocp.2017.12.003 PubMedCrossRef

80.

C.S. Marathe, C.K. Rayner, K.L. Jones, M. Horowitz, Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 36, 1396–1405 (2013). https://doi.org/10.2337/dc12-1609 PubMedPubMedCentralCrossRef

81.

G.S. Papaetis, Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J. Diabetes 5, 817–834 (2014). https://doi.org/10.4239/wjd.v5.i6.817 PubMedPubMedCentralCrossRef

82.

J. Bland, Intestinal microbiome, akkermansia muciniphila, and medical nutrition therapy. Integr. Med. (Encinitas). 15, 14–16 (2016). https://doi.org/10.1136/gutjnl-2015-310904 CrossRefPubMedPubMedCentral

83.

K. Forslund, F. Hildebrand, T. Nielsen, G. Falony, E. Le Chatelier, S. Sunagawa, E. Prifti, S. Vieira-Silva, V. Gudmundsdottir, H. Krogh Pedersen, M. Arumugam, K. Kristiansen, A. Yvonne Voigt, H. Vestergaard, R. Hercog, P. Igor Costea, J. Roat Kultima, J. Li, T. Jørgensen, F. Levenez, J. Dore, H. Bjørn Nielsen, S. Brunak, J. Raes, T. Hansen, J. Wang, S. Dusko Ehrlich, P. Bork, O. Pedersen, Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262–266 (2015). https://doi.org/10.1038/nature15766 PubMedPubMedCentralCrossRef

84.

N.M. Maruthur, E. Tseng, S. Hutfless, L.M. Wilson, C. Suarez-Cuervo, Z. Berger, Y. Chu, E. Iyoha, J.B. Segal, S. Bolen, Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann. Intern. Med. 164, 740–751 (2016)PubMedCrossRef

85.

D. Kopelman, I. Caterson, J. Michael, W. HD, Clinical obesity in adults and children. (2009)

86.

K.M. Levri, E. Slaymaker, A. Last, J. Yeh, J. Ference, F. D’Amico, S.A. Wilson, Metformin as treatment for overweight and obese adults: A systematic review. Ann. Fam. Med. 3, 457–461 (2005)PubMedPubMedCentralCrossRef

87.

M.P. van der Aa, M.A.J. Elst, E.M.W. van de Garde, E.G.A.H. van Mil, C.A.J. Knibbe, M.M.J. van der Vorst, Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr. Diabetes 6, e228 (2016). https://doi.org/10.1038/nutd.2016.37 PubMedPubMedCentralCrossRef

88.

U. Uusitalo, X. Liu, J. Yang, C.A. Aronsson, S. Hummel, M. Butterworth, Å. Lernmark, M. Rewers, W. Hagopian, J.-X. She, O. Simell, J. Toppari, A.G. Ziegler, B. Akolkar, J. Krischer, J.M. Norris, S.M. Virtanen; TEDDY Study Group, Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr. 33612, 1–9 (2015). https://doi.org/10.1001/jamapediatrics.2015.2757 CrossRef

89.

W.-H. Lee, P.-C. Hsu, C.-Y. Chu, H.-M. Su, C.-S. Lee, H.-W. Yen, T.-H. Lin, W.-C. Voon, W.-T. Lai, S.-H. Sheu, Cardiovascular events in patients with atherothrombotic disease: a population-based longitudinal study in Taiwan. PLoS. One. 9, e92577 (2014). https://doi.org/10.1371/journal.pone.0092577 PubMedPubMedCentralCrossRef

90.

C. Gazzaruso, S.B. Solerte, E. De Amici, M. Mancini, A. Pujia, P. Fratino, A. Giustina, A. Garzaniti, Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus. Am. J. Cardiol. 97, 236–239 (2006). https://doi.org/10.1016/j.amjcard.2005.07.133 PubMedCrossRef

91.

C. Gazzaruso, A. Coppola, A. Giustina, Erectile dysfunction and coronary artery disease in patients with diabetes. Curr. Diabetes Rev. 7, 143–147 (2011). https://doi.org/10.2174/157339911794940693 PubMedCrossRef

92.

G.S. Crowther, M.H. Wilcox, Antibiotic therapy and Clostridium difficile infection -primum non nocere - first do no harm. Infect. Drug Resist. 8, 333–337 (2015). https://doi.org/10.2147/IDR.S87224 PubMedPubMedCentralCrossRef

93.

W.H.W. Tang, Z. Wang, D.J. Kennedy, Y. Wu, J.A. Buffa, B. Agatisa-Boyle, X.S. Li, B.S. Levison, S.L. Hazen, Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116, 448–455 (2015). https://doi.org/10.1161/CIRCRESAHA.116.305360 PubMedCrossRef

94.

R.A. Koeth, Z. Wang, B.S. Levison, J.A. Buffa, E. Org, B.T. Sheehy, E.B. Britt, X. Fu, Y. Wu, L. Li, J.D. Smith, J.A. Didonato, J. Chen, H. Li, G.D. Wu, J.D. Lewis, M. Warrier, J.M. Brown, R.M. Krauss, W.H.W. Tang, F.D. Bushman, A.J. Lusis, S.L. Hazen, Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013). https://doi.org/10.1038/nm.3145 PubMedPubMedCentralCrossRef

95.

R.A. Koeth, B.S. Levison, M.K. Culley, J.A. Buffa, Z. Wang, J.C. Gregory, E. Org, Y. Wu, L. Li, J.D. Smith, W.H.W. Tang, J.A. Didonato, A.J. Lusis, S.L. Hazen, γ-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell. Metab. 20, 799–812 (2014). https://doi.org/10.1016/j.cmet.2014.10.006 PubMedPubMedCentralCrossRef

96.

W.H.W. Tang, Z. Wang, Y. Fan, B. Levison, J.E. Hazen, L.M. Donahue, Y. Wu, S.L. Hazen, Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: Refining the gut hypothesis. J. Am. Coll. Cardiol. 64, 1908–1914 (2014)PubMedCrossRef

97.

W.P. Fay, Homocysteine and thrombosis: Guilt by association? Blood 119, 2977–2978 (2012)PubMedCrossRef

98.

R. Ostan, M.C. Béné, L. Spazzafumo, A. Pinto, L.M. Donini, F. Pryen, Z. Charrouf, L. Valentini, H. Lochs, I. Bourdel-Marchasson, C. Blanc-Bisson, F. Buccolini, P. Brigidi, C. Franceschi, P.A. d’Alessio, Impact of diet and nutraceutical supplementation on inflammation in elderly people. Results from the RISTOMED study, an open-label randomized control trial. Clin. Nutr. 35, 812–818 (2016). https://doi.org/10.1016/j.clnu.2015.06.010 PubMedCrossRef

99.

J.L. Griffin, X. Wang, E. Stanley, Does Our gut microbiome predict cardiovascular risk? A review of the evidence from metabolomics. Circ. Cardiovasc Genet. 8, 187–191 (2015)PubMedPubMedCentralCrossRef

100.

J. Joseph, J. Loscalzo, Nutri(meta)genetics and cardiovascular disease: novel concepts in the interaction of diet and genomic variation. Curr. Atherosler Rep. 17, 505 (2015)

101.

W.H.W. Tang, S.L. Hazen, The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest. 124, 4204–4211 (2014). https://doi.org/10.1172/JCI72331 PubMedPubMedCentralCrossRef

102.

T. Yang, M.M. Santisteban, V. Rodriguez, E. Li, N. Ahmari, J.M. Carvajal, M. Zadeh, M. Gong, Y. Qi, J. Zubcevic, B. Sahay, C.J. Pepine, M.K. Raizada, M. Mohamadzadeh, Gut dysbiosis is linked to hypertension. Hypertension 65, 1331–1340 (2015). https://doi.org/10.1161/HYPERTENSIONAHA.115.05315 PubMedPubMedCentralCrossRef

103.

X.T. Gan, G. Ettinger, C.X. Huang, J.P. Burton, J.V. Haist, V. Rajapurohitam, J.E. Sidaway, G. Martin, G.B. Gloor, J.R. Swann, G. Reid, M. Karmazyn, Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ. Hear. Fail. 7, 491–499 (2014). https://doi.org/10.1161/CIRCHEARTFAILURE.113.000978 CrossRef

104.

C.S. Hampe, C.L. Roth, Probiotic strains and mechanistic insights for the treatment of type 2 diabetes. Endocrine 58, 207–227 (2017). https://doi.org/10.1007/s12020-017-1433-z PubMedCrossRef

105.

M.H. Floch, Probiotics and prebiotics. Gastroenterol. Hepatol. (N. Y) 10, 680–681 (2014)

106.

M.C. Dao, A. Everard, J. Aron-Wisnewsky, N. Sokolovska, E. Prifti, E.O. Verger, B.D. Kayser, F. Levenez, J. Chilloux, L. Hoyles, M.-E. Dumas, S.W. Rizkalla, J. Doré, P.D. Cani, K. Clément, Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426–436 (2016)PubMedCrossRef

107.

C. Chevalier, O. Stojanović, D.J. Colin, N. Suarez-Zamorano, V. Tarallo, C. Veyrat-Durebex, D. Rigo, S. Fabbiano, A. Stevanović, S. Hagemann, X. Montet, Y. Seimbille, N. Zamboni, S. Hapfelmeier, M. Trajkovski, Gut microbiota orchestrates energy homeostasis during cold. Cell 163, 1360–1374 (2015). https://doi.org/10.1016/j.cell.2015.11.004 PubMedCrossRef

108.

L.J. Cohen, D. Esterhazy, S.-H. Kim, C. Lemetre, R.R. Aguilar, E.A. Gordon, A.J. Pickard, J.R. Cross, A.B. Emiliano, S.M. Han, J. Chu, X. Vila-Farres, J. Kaplitt, A. Rogoz, P.Y. Calle, C. Hunter, J.K. Bitok, S.F. Brady, Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 549, 48–53 (2017). https://doi.org/10.1038/nature23874 PubMedPubMedCentralCrossRef

109.

M. Mimee, R.J. Citorik, T.K. Lu, Microbiome therapeutics—Advances and challenges. Adv. Drug. Deliv. Rev. 105, 44–54 (2016)PubMedPubMedCentralCrossRef

110.

Z.Z.R. Hamady, N. Scott, M.D. Farrar, M. Wadhwa, P. Dilger, T.R. Whitehead, R. Thorpe, K.T. Holland, J.P.A. Lodge, S.R. Carding, Treatment of colitis with a commensal gut bacterium engineered to secrete human tgf-β1 under the control of dietary xylan 1. Inflamm. Bowel. Dis. 17, 1925–1935 (2011). https://doi.org/10.1002/ibd.21565 PubMedCrossRef

111.

K. Vandenbroucke, H. De Haard, E. Beirnaert, T. Dreier, M. Lauwereys, L. Huyck, J. Van Huysse, P. Demetter, L. Steidler, E. Remaut, C. Cuvelier, P. Rottiers, Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3, 49–56 (2010). https://doi.org/10.1038/mi.2009.116 PubMedCrossRef

112.

Z.Z.R. Hamady, N. Scott, M.D. Farrar, J.P.A. Lodge, K.T. Holland, T. Whitehead, S.R. Carding, Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 59, 461–469 (2010)PubMedCrossRef

113.

J.P. Motta, L.G. Bermúdez-Humarán, C. Deraison, L. Martin, C. Rolland, P. Rousset, J. Boue, G. Dietrich, K. Chapman, P. Kharrat, J.P. Vinel, L. Alric, E. Mas, J.M. Sallenave, P. Langella, N. Vergnolle, Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci. Transl. Med. 4, 158ra144 (2012). https://doi.org/10.1126/scitranslmed.3004212 PubMedCrossRef

114.

G.R. Gibson, H.M. Probert, J.Van Loo, R.A. Rastall, M.B. Roberfroid, Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr. Res. Rev. 17, 259 (2004). https://doi.org/10.1079/NRR200479 PubMedCrossRef

115.

J. Slavin, Fiber and prebiotics: mechanisms and health benefits. Nutrients 5, 1417–1435 (2013). https://doi.org/10.3390/nu5041417 PubMedPubMedCentralCrossRef

116.

M. De Vrese, J. Schrezenmeir, Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 111, 1–66 (2008)PubMed

117.

B.C. Tungland, D. Meyer, Nondigestible oligo- and polysaccharides (dietary fiber): Their physiology and role in human health and food. Compr. Rev. Food Sci. Food Saf. 1, 90–109 (2002). https://doi.org/10.1111/j.1541-4337.2002.tb00009.x CrossRef

118.

Z. Wang, E. Klipfell, B.J. Bennett, R. Koeth, B.S. Levison, B. Dugar, A.E. Feldstein, E.B. Britt, X. Fu, Y.M. Chung, Y. Wu, P. Schauer, J.D. Smith, H. Allayee, W.H.W. Tang, J.A. Didonato, A.J. Lusis, S.L. Hazen, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–65 (2011). https://doi.org/10.1038/nature09922 PubMedPubMedCentralCrossRef

119.

A. Coppola, L. Sasso, A. Bagnasco, A. Giustina, C. Gazzaruso, The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine 53, 18–27 (2016)PubMedCrossRef

120.

V. Tosti, B. Bertozzi, L. Fontana, Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms. J Gerontol A Biol Sci Med Sci. 73, 318–326 (2018)PubMedCrossRef

121.

T.T.B. Nguyen, Y.Y. Jin, H.J. Chung, S.T. Hong, Pharmabiotics as an emerging medication for metabolic syndrome and its related diseases. Molecules 22(10), E1795 (2017)PubMedCrossRef

122.

R.E. Ley, D.A. Peterson, J.I. Gordon, Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837–848 (2006). https://doi.org/10.1016/J.CELL.2006.02.017 PubMedCrossRef

123.

R.E. Ley, F. Bäckhed, P. Turnbaugh, C.A. Lozupone, R.D. Knight, J.I. Gordon, Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. U. S. A. 102, 11070–11075 (2005). https://doi.org/10.1073/pnas.0504978102 PubMedPubMedCentralCrossRef

124.

A.L. Komaroff, The microbiome and risk for obesity and diabetes. JAMA 317, 355 (2017). https://doi.org/10.1001/jama.2016.20099 PubMedCrossRef

125.

S.K. Mazmanian, J.L. Round, D.L. Kasper, A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620–625 (2008). https://doi.org/10.1038/nature07008 PubMedCrossRef

126.

L. Wen, R.E. Ley, P.Y. Volchkov, P.B. Stranges, L. Avanesyan, A.C. Stonebraker, C. Hu, F.S. Wong, G.L. Szot, J.A. Bluestone, J.I. Gordon, A.V. Chervonsky, Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 455, 1109–1113 (2008). https://doi.org/10.1038/nature07336 PubMedPubMedCentralCrossRef

127.

Y.S. Kim, J.A. Milner, Dietary modulation of colon cancer risk. J. Nutr. 137, 2576S–2579S (2007)PubMedCrossRef

128.

S.K.P. Lau, P.C.Y. Woo, G.K.S. Woo, A.M.Y. Fung, M.K.M. Wong, K.-M. Chan, D.M.W. Tam, K.-Y. Yuen, Eggerthella hongkongensis sp. nov. and eggerthella sinensis sp. nov., two novel Eggerthella species, account for half of the cases of Eggerthella bacteremia. Diagn. Microbiol. Infect. Dis. 49, 255–263 (2004). https://doi.org/10.1016/j.diagmicrobio.2004.04.012 PubMedCrossRef

129.

M. Kraatz, R.J. Wallace, L. Svensson, Olsenella umbonata sp. nov., a microaerotolerant anaerobic lactic acid bacterium from the sheep rumen and pig jejunum, and emended descriptions of Olsenella, Olsenella uli and Olsenella profusa. Int. J. Syst. Evol. Microbiol. 61, 795–803 (2011). https://doi.org/10.1099/ijs.0.022954-0 PubMedCrossRef

130.

S.K. Lau, P.C. Woo, A.M. Fung, K. Chan, G.K. Woo, K. Yuen, Anaerobic, non-sporulating, Gram-positive bacilli bacteraemia characterized by 16S rRNA gene sequencing. J. Med. Microbiol. 53, 1247–1253 (2004). https://doi.org/10.1099/jmm.0.45803-0 PubMedCrossRef

131.

A. Finamore, M. Palmery, S. Bensehaila, I. Peluso, Antioxidant, immunomodulating, and microbial-modulating activities of the sustainable and ecofriendly Spirulina. Oxid. Med. Cell Longev. 2017, 3247528 (2017). https://doi.org/10.1155/2017/3247528. 1–14PubMedPubMedCentralCrossRef

132.

D.J. Hampson, T. La, N.D. Phillips, Emergence of Brachyspira species and strains: reinforcing the need for surveillance. Porc. Heal. Manag. 1, 8 (2015). https://doi.org/10.1186/s40813-015-0002-1 CrossRef

133.

M.Y. Galperin, New feel for new phyla. Environ. Microbiol. 10, 1927–1933 (2008). https://doi.org/10.1111/j.1462-2920.2008.01699.x PubMedPubMedCentralCrossRef

134.

M. Yamauchi, P. Lochhead, T. Morikawa, C. Huttenhower, A.T. Chan, E. Giovannucci, C. Fuchs, S. Ogino, Colorectal cancer: a tale of two sides or a continuum? Gut 61, 794–797 (2012). https://doi.org/10.1136/gutjnl-2012-302014 PubMedPubMedCentralCrossRef

Titel: Microbiota and metabolic diseases
verfasst von: Alessia Pascale
Nicoletta Marchesi
Cristina Marelli
Adriana Coppola
Livio Luzi
Stefano Govoni
Andrea Giustina
Carmine Gazzaruso
Publikationsdatum: 02.05.2018
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1605-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Microbiota and metabolic diseases

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Novel mutation of PPOX gene in a patient with abdominal pain and syndrome of inappropriate antidiuresis

More sugar? No, thank you! The elusive nature of low carbohydrate diets

The posterior pharyngeal wall thickness is associated with OSAHS in patients with acromegaly and correlates with IGF-1 levels

Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection

Assessing the utility of preoperative serum thyroglobulin in differentiated thyroid cancer: a retrospective cohort study

Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin